Loading...
Loading...
CHRS| Name | Value |
|---|---|
| Revenues | 32.4M |
| Cost of Revenue | 16.9M |
| Gross Profit | 15.6M |
| Operating Expense | 83.3M |
| Operating I/L | -67.7M |
| Other Income/Expense | -8.0M |
| Interest Income | 9.7M |
| Pretax | -75.7M |
| Income Tax Expense | -0.9M |
| Net Income/Loss | -74.8M |
Coherus BioSciences, Inc. is a biopharmaceutical company specializing in biosimilars and immuno-oncology products in the United States. The company's flagship product, UDENYCA, is a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. Coherus BioSciences also has a robust pipeline of biosimilars including Humira, Avastin, and Lucentis. Additionally, the company is developing innovative products such as Toripalimab, a novel anti-PD-1 antibody for melanoma treatment, and biosimilars of Bevacizumab, adalimumab, and ranibizumab. Coherus BioSciences has established license agreements with prominent biopharmaceutical companies, driving its revenue through product sales and licensing partnerships.
